Company: MD Anderson
Job title: Associate Professor
Dr. Simrit Parmar is a Tenured Associate Professor in the department of Lymphoma and Myeloma at MD Anderson Cancer Center, Houston as well as Experimental Therapeutics at MD Anderson Cancer Center, Texas. Her basic science research interest is focused on regulatory T cells, their involvement in disease pathogenesis and prevention of autoimmune disorders and inflammatory disorders including Graft versus Host Disease and Cytokine Release Syndrome.
Dr. Parmar is the principal investigator of research laboratory focused on cord blood derived regulatory T cells including their isolation and ex-vivo expansion for generating clinically relevant dose for their application in autoimmune diseases and inflammatory disorders. She has published her work in peer reviewed journals and her research has been translated into a pilot study of 3rd party cord blood regulatory T cells for prevention of graft versus host disease. This phase I/II trial shows complete prevention of GVHD at a dose of 1×10^7 CB T-reg cells/kg in patient undergoing matched unrelated donor peripheral blood transplantation. A total of 5 out of 6 patients are alive, in disease remission with no evidence of GVHD or dependence on immune suppression at a 3 year follow up. Her research has been funded by peer reviewed grants. She was also the proud recipient of the inaugural R. Lee Clark Fellowship award. In addition, she is actively involved with the global academic program as well as MD Anderson Cancer Network program. Dr. Parmar is one of the founding members of the Asia Pacific Hematology Consortium that focuses on advancing the field of hematology oncology through continued education, collaboration and fostering innovations. Dr. Parmar received her hematology / oncology fellowship training at Northwestern University and bone marrow transplant fellowship at MD Anderson Cancer Center.
Based on the technologies arising from the laboratory investigations of Simrit Parmar, M.D., The University of Texas at MD Anderson Cancer Center and Golden Meditech Holdings Limited, a Hong Kong-based integrated healthcare enterprise have created Cellenkos, Inc., a start-up enterprise focused on umbilical cord blood derived T-regulatory (“T-reg”) cellular therapies. The first generation, allogeneic, CB T-reg product is in phase I Clinical trial as a single agent for the treatment of bone marrow failure syndromes including primary myelofibrosis, myelodysplasia and aplastic anemia. The second generation, allogeneic CB T-reg product will be tested in a phase I trial for the treatment of the neuro-inflammatory disorder of amyotrophic lateral sclerosis.
Adoptive Therapy with Allogeneic, Cord Blood Regulatory T Cells for Treatment of Inflammatory Bone Marrow Disorders & GVHD 9:30 am
What is different about cord blood regulatory T cells? Phase I/ II data of using allogeneic cord blood regulatory T cells for the prevention of GVHD Phase I data of using allogeneic cord blood regulatory T cells for the treatment of inflammatory bone marrow disordersRead more
day: Day One